PL3157548T3 - Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym - Google Patents

Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym

Info

Publication number
PL3157548T3
PL3157548T3 PL15741128T PL15741128T PL3157548T3 PL 3157548 T3 PL3157548 T3 PL 3157548T3 PL 15741128 T PL15741128 T PL 15741128T PL 15741128 T PL15741128 T PL 15741128T PL 3157548 T3 PL3157548 T3 PL 3157548T3
Authority
PL
Poland
Prior art keywords
therapy
factor xii
xii inhibitor
neurotraumatic disorder
neurotraumatic
Prior art date
Application number
PL15741128T
Other languages
English (en)
Inventor
Christoph Kleinschnitz
Marc Nolte
Anna-Leena SIRÉN
Christiane ALBERT-WEISSENBERGER
Sarah Hopp-Kraemer
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL3157548T3 publication Critical patent/PL3157548T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL15741128T 2014-06-18 2015-06-18 Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym PL3157548T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14172910 2014-06-18
EP15741128.1A EP3157548B1 (en) 2014-06-18 2015-06-18 Therapy using a factor xii inhibitor in a neurotraumatic disorder
PCT/EP2015/063760 WO2015193457A1 (en) 2014-06-18 2015-06-18 Therapy using a factor xii inhibitor in a neurotraumatic disorder

Publications (1)

Publication Number Publication Date
PL3157548T3 true PL3157548T3 (pl) 2022-01-17

Family

ID=50972542

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15741128T PL3157548T3 (pl) 2014-06-18 2015-06-18 Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym

Country Status (12)

Country Link
US (2) US20170114119A1 (pl)
EP (1) EP3157548B1 (pl)
JP (1) JP7109160B2 (pl)
KR (1) KR102513050B1 (pl)
CN (1) CN106456778A (pl)
AU (1) AU2015276089B2 (pl)
BR (1) BR112016029624A2 (pl)
CA (1) CA2950988C (pl)
DK (1) DK3157548T3 (pl)
ES (1) ES2886859T3 (pl)
PL (1) PL3157548T3 (pl)
WO (1) WO2015193457A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7109160B2 (ja) 2014-06-18 2022-07-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法
PL3436009T3 (pl) * 2016-03-30 2024-05-06 Sinntaxis AB Ujemne modulatory allosteryczne mglur5 do użycia w leczeniu rozwiniętych uszkodzeń mózgu
CN109071629A (zh) * 2016-04-06 2018-12-21 杰特有限公司 治疗动脉粥样硬化的方法
JP7317827B2 (ja) 2017-12-15 2023-07-31 シーエスエル、リミテッド 腎線維症および／または慢性腎臓疾患の治療におけるＦＸＩＩａインヒビターの使用
WO2020113084A1 (en) * 2018-11-28 2020-06-04 Oregon Health & Science University Therapeutic factor xii antibody

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
CA2082643A1 (en) 1990-05-10 1991-11-11 Jan H. Nuijens Inhibitors of factor xii activation and applications thereof
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
EP0793504B1 (en) 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
CN1871252A (zh) 2003-09-05 2006-11-29 Gtc生物治疗学公司 在转基因哺乳动物奶中生产融合蛋白的方法
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
AU2005318464B2 (en) * 2004-12-23 2012-02-23 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization
ES2566385T3 (es) 2007-02-12 2016-04-12 Csl Behring Gmbh Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal
WO2011069090A1 (en) 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
KR20230116964A (ko) 2010-12-17 2023-08-04 셀룰래리티 인코포레이티드 태반 줄기 세포를 이용하는 척수 손상 및 외상성 뇌손상의 치료
WO2012120128A1 (en) 2011-03-09 2012-09-13 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
EP2548892A1 (en) * 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
MX347454B (es) 2011-07-22 2017-04-27 Csl Ltd Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
EP2758076B1 (en) 2011-09-24 2018-12-12 CSL Behring GmbH Combination therapy using immunoglobulin and c1-inhibitor
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
KR20160026905A (ko) * 2013-06-28 2016-03-09 체에스엘 베링 게엠베하 인자 ｘｉｉ 억제제 및 ｃ1-억제제를 이용한 병용 치료요법
US9587903B2 (en) 2014-02-24 2017-03-07 Brian E. Sullivan Pneumatic launcher system and method
JP7109160B2 (ja) 2014-06-18 2022-07-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法
CN109071629A (zh) 2016-04-06 2018-12-21 杰特有限公司 治疗动脉粥样硬化的方法

Also Published As

Publication number Publication date
ES2886859T3 (es) 2021-12-21
KR102513050B1 (ko) 2023-03-29
US20200131248A1 (en) 2020-04-30
CN106456778A (zh) 2017-02-22
US12065481B2 (en) 2024-08-20
JP2017524675A (ja) 2017-08-31
AU2015276089B2 (en) 2021-03-18
EP3157548A1 (en) 2017-04-26
EP3157548B1 (en) 2021-08-04
KR20170016503A (ko) 2017-02-13
CA2950988A1 (en) 2015-12-23
DK3157548T3 (da) 2021-09-06
WO2015193457A1 (en) 2015-12-23
BR112016029624A2 (pt) 2017-10-24
CA2950988C (en) 2024-02-06
US20170114119A1 (en) 2017-04-27
JP7109160B2 (ja) 2022-07-29
AU2015276089A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
HK1210935A1 (en) A massage chair having curved track
GB201517416D0 (en) Task-execution in a DBMS using stored procedures
GB201409535D0 (en) Arranging components in a two-dimensional area
PL3165360T3 (pl) Laminat
SG11201607597SA (en) A stair
HUE051268T2 (hu) Immunellenõrzõpont-gátló kombinációk
GB201405033D0 (en) Combination therapy
GB2531324B (en) A stylus
HK1245461A1 (zh) 計數裝置的改進
SG11201508893YA (en) Laminate
PL3157548T3 (pl) Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
GB201416500D0 (en) A chair back
GB2523128B (en) Improvements in or relating to a secondary drive unit
GB201322628D0 (en) A game apparatus
IL249240A0 (en) Combined treatment
GB2526425B (en) A face guard
EP3739138C0 (en) PLAYGROUND
TWI561187B (en) A furniture device
GB201311986D0 (en) A training shoe
GB201513859D0 (en) A Laminate structure
GB201511147D0 (en) A laminate structure
GB201502436D0 (en) A phototherapy device
AU356454S (en) A chair
FI10846U1 (fi) Sovitelma saunan yhteydessä